AU2015217185B2 - Isoquinoline derivatives and use thereof - Google Patents

Isoquinoline derivatives and use thereof Download PDF

Info

Publication number
AU2015217185B2
AU2015217185B2 AU2015217185A AU2015217185A AU2015217185B2 AU 2015217185 B2 AU2015217185 B2 AU 2015217185B2 AU 2015217185 A AU2015217185 A AU 2015217185A AU 2015217185 A AU2015217185 A AU 2015217185A AU 2015217185 B2 AU2015217185 B2 AU 2015217185B2
Authority
AU
Australia
Prior art keywords
alkyl
amino
compound
group
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015217185A
Other languages
English (en)
Other versions
AU2015217185A1 (en
Inventor
Jae Hyun Park
Laykea Tafesse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of AU2015217185A1 publication Critical patent/AU2015217185A1/en
Application granted granted Critical
Publication of AU2015217185B2 publication Critical patent/AU2015217185B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015217185A 2014-02-12 2015-02-12 Isoquinoline derivatives and use thereof Active AU2015217185B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461939082P 2014-02-12 2014-02-12
US61/939,082 2014-02-12
PCT/US2015/015576 WO2015123398A1 (en) 2014-02-12 2015-02-12 Isoquinoline derivatives and use thereof

Publications (2)

Publication Number Publication Date
AU2015217185A1 AU2015217185A1 (en) 2016-09-01
AU2015217185B2 true AU2015217185B2 (en) 2018-04-05

Family

ID=53800620

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015217185A Active AU2015217185B2 (en) 2014-02-12 2015-02-12 Isoquinoline derivatives and use thereof

Country Status (8)

Country Link
US (2) US10738026B2 (https=)
EP (1) EP3105217B1 (https=)
JP (1) JP6556154B2 (https=)
CN (1) CN106103422B (https=)
AU (1) AU2015217185B2 (https=)
CA (1) CA2939501C (https=)
IL (1) IL247252B (https=)
WO (1) WO2015123398A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2917182B1 (en) 2012-11-09 2018-01-03 Purdue Pharma LP Benzomorphan analogs and the use thereof
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
CA2939549C (en) 2013-03-15 2020-08-18 Purdue Pharma L.P. Carboxamide derivatives and use thereof
CN105612152A (zh) 2013-08-26 2016-05-25 普渡制药公司 氮杂螺[4.5]癸烷衍生物及其用途
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
JP6337124B2 (ja) 2013-12-23 2018-06-06 パーデュー、ファーマ、リミテッド、パートナーシップ インダゾール及びその使用
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
EP3087057A4 (en) 2013-12-26 2017-06-28 Purdue Pharma LP Ring-contracted morphinans and the use thereof
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
JP6526023B2 (ja) 2014-01-24 2019-06-05 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン類及びピリミジン類並びにその使用
CA2950567A1 (en) 2014-05-27 2015-12-03 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
MA40171A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
CN110325516A (zh) * 2016-12-29 2019-10-11 米尼奥尔克斯治疗有限公司 杂芳基化合物和它们的用途
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
US11505529B2 (en) * 2017-03-03 2022-11-22 National Taiwan University 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome
WO2019079369A1 (en) 2017-10-19 2019-04-25 Effector Therapeutics, Inc. BENZIMIDAZOLE INDOLE INHIBITORS OF MNK1 AND MNK2
CN110372584A (zh) * 2019-06-25 2019-10-25 南京普锐达医药科技有限公司 一种2,4-二氯-6-氰基嘧啶的合成方法
WO2023139581A1 (en) * 2022-01-18 2023-07-27 Bsense Bio Therapeutics Ltd. Modulators of a potassium channel and of trpv1 channel and uses thereof
CA3248820A1 (en) * 2022-01-28 2023-08-03 Opna Bio SA COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND RELATED INDICATIONS
WO2024210578A1 (ko) * 2023-04-05 2024-10-10 주식회사 바오밥에이바이오 헤테로비시클릭 화합물 및 그를 포함하는 약제학적 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223170A1 (en) * 1999-10-12 2002-07-17 Takeda Chemical Industries, Ltd. Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
WO2007148185A2 (en) * 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
US20110195954A1 (en) * 2007-11-22 2011-08-11 Boehringer Ingelheim International Gmbh Novel compounds
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2011105572A1 (ja) * 2010-02-26 2011-09-01 持田製薬株式会社 新規ヘテロアリール誘導体
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500590A (en) 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
EP1032377B1 (en) 1997-11-21 2010-11-17 Purdue Neuroscience Company Substituted 2-aminoacetamides and the use thereof
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
TW502019B (en) 1999-03-26 2002-09-11 Cocensys Inc Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
DK1169060T3 (da) 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
AU4589701A (en) 2000-03-24 2001-10-08 Cocensys Inc Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
AU4961001A (en) 2000-03-31 2001-10-15 Cocensys Inc Aminopyridines and their use as anticonvulsants and sodium channel blockers
IL159765A0 (en) 2001-07-16 2004-06-20 Euro Celtique Sa Aryl substituted thiazolidinone derivatives and pharmaceutical compositions containing the same
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
MXPA04008901A (es) 2002-03-13 2004-11-26 Euro Celtique Sa Pirimidinas arilo sustituidas y el uso de las mismas.
CA2492305A1 (en) 2002-07-31 2004-02-05 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US20040097569A1 (en) 2002-07-31 2004-05-20 Euro-Celtique S.A. Aryl substituted hydantoin compounds and their use as sodium channel blockers
US20040152696A1 (en) 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7767680B2 (en) * 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
WO2010022055A2 (en) * 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
WO2011141474A1 (en) * 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2582666B1 (en) 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
AU2011303597A1 (en) 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
KR20130095772A (ko) 2010-10-05 2013-08-28 퍼듀 퍼머 엘피 나트륨 채널 차단제로서 퀴나졸린 화합물
EP2655330B1 (en) 2010-12-22 2016-02-10 Purdue Pharma LP Substituted pyridines as sodium channel blockers
CA2826464C (en) 2011-03-02 2020-07-28 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
EP3255041A1 (en) 2011-09-02 2017-12-13 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
WO2013064884A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013064883A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
US9133131B2 (en) 2011-11-15 2015-09-15 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
EP2935257B1 (en) 2012-12-20 2018-02-07 Purdue Pharma LP Cyclic sulfonamides as sodium channel blockers
WO2014135955A1 (en) 2013-03-04 2014-09-12 Purdue Pharma L.P. Pyrimidine carboxamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
CA2939549C (en) 2013-03-15 2020-08-18 Purdue Pharma L.P. Carboxamide derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223170A1 (en) * 1999-10-12 2002-07-17 Takeda Chemical Industries, Ltd. Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
WO2007148185A2 (en) * 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
US20110195954A1 (en) * 2007-11-22 2011-08-11 Boehringer Ingelheim International Gmbh Novel compounds
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2011105572A1 (ja) * 2010-02-26 2011-09-01 持田製薬株式会社 新規ヘテロアリール誘導体
WO2012135697A2 (en) * 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center & Research Institute Inc. Novel rho kinase inhibitors and methods of use

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1000301-68-7; STN Entry Date 18 Jan 2008; 2-[4-[(3S,4S)-3-amino-4-(2-oxo-1-piperidinyl)-1-pyrrolidinyl]-1,3,5-triazin-2-yl]-1,2,3,4-tetrahydro-N-methyl-5-Isoquinolinesulfonamide *
CAS Registry Number 1259151-79-5; STN Entry Date 12 Jan 2011; N-[2-(6-chloro-2-methyl-4-pyrimidinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]-acetamide *
CAS Registry Number 1260840-55-8; STN Entry Date 27 Jan 2011; 2-[6-chloro-5-methyl-2-(4-morpholinyl)-4-pyrimidinyl]-1,2,3,4-tetrahydro-5-methoxy-isoquinoline *
CAS Registry Number 1347388-20-8; STN Entry Date 02 Dec 2011; N-[2-[5-(fluoromethyl)-3,4-dihydro-8-methyl-2(1H)-isoquinolinyl]-4,6-dimethyl-5-pyrimidinyl]-cyclopentaneacetamide *
CAS Registry Number 1356753-38-2; STN Entry Date 14 Feb 2012; 1-[2-(4-amino-2-pyrimidinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]-5-methyl-N-(phenylmethyl)- 1H-1,2,3-triazole-4-carboxamide *
CAS Registry Number 1384681-05-3; STN Entry Date 27 Jul 2012; 1-[6-(3,4-dihydro-5-methyl-2(1H)-isoquinolinyl)-4-pyrimidinyl]-2-pyrrolidinemethanol *
CAS Registry Number 1394435-36-9; STN Entry Date 18 Sep 2012; (2-amino-4-pyridinyl)[3,4-dihydro-5-(4-morpholinylsulfonyl)-2(1H)-isoquinolinyl-methanone *
CAS Registry Number 1423750-33-7; STN Entry Date 14 Mar 2013; N-[2-[(2-cyano-4-pyridinyl)methyl]-1,2,3,4-tetrahydro-5-isoquinolinyl- acetamide *
CAS Registry Number 1436255-28-5; STN Entry Date 9 June 2013; 3-[2-[(2-chloro-4-pyridinyl)methyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]-2-oxazolidinone *

Also Published As

Publication number Publication date
US11401258B2 (en) 2022-08-02
JP6556154B2 (ja) 2019-08-07
EP3105217B1 (en) 2019-05-29
AU2015217185A1 (en) 2016-09-01
US20200407338A1 (en) 2020-12-31
CN106103422B (zh) 2020-09-18
JP2017511794A (ja) 2017-04-27
US20170057942A1 (en) 2017-03-02
IL247252B (en) 2020-04-30
IL247252A0 (en) 2016-09-29
US10738026B2 (en) 2020-08-11
CA2939501C (en) 2020-07-07
CN106103422A (zh) 2016-11-09
EP3105217A4 (en) 2017-08-09
EP3105217A1 (en) 2016-12-21
CA2939501A1 (en) 2015-08-20
WO2015123398A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
US11401258B2 (en) Isoquinoline derivatives and use thereof
US11834447B2 (en) Indole derivatives and use thereof
US10155752B2 (en) Indazoles and use thereof
US11180502B2 (en) Azaspiro[4.5]decane derivatives and use thereof
AU2017204263B2 (en) Carboxamide derivatives and use thereof
EP3097078B1 (en) Pyridines and pyrimidines and use thereof
US10000475B2 (en) Triazine carboxamides as sodium channel blockers
EP3083606B1 (en) Pyrimidines and use thereof
US9359330B2 (en) Substituted piperidines as sodium channel blockers
US10125113B2 (en) Dibenzazepine derivatives and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)